Introduction
============

A high prevalence of *Pneumocystis jirovecii* colonization was observed in patients with chronic pulmonary diseases or various lung underlying diseases,[@b1-copd-10-2079]--[@b3-copd-10-2079] and the important roles of *P. jirovecii* colonization in development or progression of various lung diseases is a concern.[@b4-copd-10-2079]--[@b6-copd-10-2079] Patients who are carriers of *P. jirovecii* are at a higher risk of *P. jirovecii* pneumonia, and could also present a problem for public health since colonized patients could act as a major reservoir and source of infection for susceptible subjects.[@b7-copd-10-2079],[@b8-copd-10-2079] Detection of carriage or colonization of *P. jirovecii* is important for understanding its epidemiology and its correlation with the lung disease. Even though a number of *Pneumocystis* pneumonia (PCP) cases has been reported in the People's Republic of China,[@b9-copd-10-2079] scarce data is available regarding the carriage or colonization of *P. jirovecii* in immunocompetent patients. Loop-mediated isothermal amplification (LAMP) is an innovative molecular technique to amplify a specific target gene.[@b10-copd-10-2079]--[@b12-copd-10-2079] To evaluate the prevalence of *P. jirovecii* colonization in patients with pulmonary diseases, we have developed and evaluated a LAMP method to detect the *P. jirovecii* gene from sputum specimens of the patients with chronic pulmonary diseases. The specimens were also microbiologically examined.

Materials and methods
=====================

Patients and specimens
----------------------

Ninety-eight HIV-negative patients suffering from chronic pulmonary diseases were incorporated in this study. They were consecutively treated in Department of Internal Medicine of the First Affiliated Hospital of China Medical University from June 2011 to October 2013. Every patient underwent a clinical and biochemical examination using a standardized protocol, and HIV antibody was tested using Anti-HIV−1+2 antibodies ELISA diagnostic kit. The patients had undergone bronchoscopy for diagnosis of various underlying respiratory diseases. The inclusion criteria was in hospital treatment for chronic pulmonary disease, including acute exacerbations of COPD (AECOPD), stable stage of COPD, interstitial lung diseases (ILDs), cystic fibrosis (CF), and chronic bronchiectasis (CB) patients. The diseases were diagnosed according to the People's Republic of China Ministry of Health in 2011 to develop the disease diagnostic criteria.

Specimen processing
-------------------

Blood and sputum specimens were collected from 98 patients before they received the corticoid or antibiotics treatment. Informed consent was obtained from all patients.

Sputum specimens were obtained from patient by spontaneous production. In order to avoid contamination of oral microbe, patients first gargled saline three times, prior to coughing up the sputum from deep respiratory tract when collecting specimens. Sputum specimens were promptly sent to the central laboratory of the hospital for bacterial culture and quantization. Co-infecting bacteria was analyzed using the automated bacterial identification system (ATB system, BioMérieux, Marcy-l'Étoile, France) following the bacterial or fungi culture. *P. jirovecii* organisms were identified microscopically by a modified Giemsa staining (Diff-Quik) method and a modified Gomori's methenamine silver nitrate staining method as previously described.[@b13-copd-10-2079],[@b14-copd-10-2079]

The blood samples were used for CD4^+^ T-cell measurement.[@b12-copd-10-2079] Sera were analyzed on BD FACSCalibur and the test kit. The normal critical value of CD4^+^ T-cell in blood was set to 410 cells/mm^3^ according to the reference of test kit. Patients will be considered as immunocompetent when CD4 cell \>410 cells/mm^3^, and they will be identified as immunocompromised when the CD4^+^ T-cell counts \<410 cells/mm^3^.

DNA preparation
---------------

DNA was extracted from the sputum specimens.[@b15-copd-10-2079] The sputa were treated with sodium hydroxide and centrifuged at 12,000 rpm for 5 minutes. The supernatant was discarded, and the precipitate was washed three times with TE buffer. Precipitated specimens were mixed with distilled water, incubated at 100°C for 15 minutes and centrifuged at 12,000 rpm for 10 minutes. The supernatants were stored at −20°C until DNA extraction. Following proteinase K digestion, DNA was extracted with a Genomic DNA Kit (Tiangen Technology, Beijing, People's Republic of China) in accordance with the manufacturer's instructions and stored at −80°C.

Design of primers
-----------------

The gene sequences of *Pneumocystis* core ribosomal bodies small subunit 16s rRNA was obtained from Gen-Bank, and compared with the 16s rRNA of *Pneumocystis carinii* (AB266392), *Pneumocystis murina* (AY532651), *Blastocystis*, and *Candida* species. The specific LAMP primer was created by web tool Primer Explorer V4 (<http://primerexplorer.jp/elamp4.0.0/index.html>). Primers and their sequences used in LAMP are showed in [Table 1](#t1-copd-10-2079){ref-type="table"}. LAMP primers F3 and B3 were also used as conventional polymerase chain reaction (PCR) primers.

LAMP assay
----------

The LAMP reaction was performed[@b11-copd-10-2079] in a final volume of 25 µL which contained 1× LAMP reaction buffer (the buffer contained 10 mM Tris-HCl (pH 8.8), 5 mM KCl, 5 mM (NH~4~)~2~SO~4~, 4 mM MgSO~4~, 0.1% Tween 20, and 0.4 M betaine (Sigma-Aldrich Co., St Louis, MO, USA)), 8 units of the Bst DNA polymerase (New England Biolabs, Ipswich, MA, USA), 100 ng of test DNA, and primers of 40 pmol (FIP and BIP), 20 pmol (Loop B and Loop F), and 5 pmol (F3 and B3). The mixture was incubated at 63°C in a water bath for 60 minutes. Detection of LAMP products was through visual fluorescence by adding 4× SYBR Green I (Thermo Fisher Scientific, Waltham, MA, USA) to 25 mL of LAMP product. The LAMP product was also electrophoresed on 1.5% agarose gel and visualized by UV gel imaging analyzer (Gel Imaging System, Shinova Co. Ltd., Shanghai, People's Republic of China); or by observing the fluorescence collection volume by a real-time PCR instrument (ABI 7500; Thermo Fisher Scientific) for 60 minutes.

PCR and plasmid preparation
---------------------------

PCR was performed with the F3 and B3 primers as forward and reverse primers to confirm their specificity. A previously described PCR technique[@b14-copd-10-2079],[@b15-copd-10-2079] was used to amplify the *Pneumocystis* mitochondrial 16s rRNA gene. PCR conditions were as follows: the reaction was denatured at 95°C for 2.5 minutes, followed by 35 cycles of amplification at 94°C for 1 minute, 65°C for 1 minute, and 72°C for 1 minute, then with a final extension step at 72°C for 5 minutes. Finally, the PCR products were analyzed by electrophoresis and stained with ethidium bromide. The PCR product was ligated into the TA cloning vector pMD18-T (Takara BIO Co., Ltd., Dalian, People's Republic of China). To prevent false-positives from contamination, pipettes with filters were used in all procedures. DNA extraction, preparation of the reaction mixture, PCR amplification, and detection were performed in separate areas under a laminar flow hood. To detect any cross-contamination, samples included a blank control or distilled water.

Sensitivity and specificity of the LAMP assay
---------------------------------------------

The sensitivity of the LAMP method was examined using serial dilutions of *Pneumocystis* DNA copies in a plasmid solution. Detection limit of LAMP were measured and compared with that of the PCR. The specificity of the LAMP detecting was validated through the parallel and comparing test with *Candida albicans*, *Candida tropicalis*, *Candida parapsilosis*, and *Candida glabrata*, *Mycoplasma pneumoniae* (FH strain), *Hemolytic streptococcus*, methicillin-resistant *Staphylococcus aureus* strains in the same condition. Equal amounts of genomic DNA for each bacterium at 100 ng were used as the template. The specificity was also compared through detecting the sputum specimens of patient, the lungs of PCP positive model rat, or negative rat (ten rats, respectively). The amplified products of LAMP were examined separately using real-time turbidity, visualized by either the naked eye or using ultraviolet light after adding SYBR Green I, and tested by gel electrophoresis. The LAMP positive product was confirmed by sequencing with 16S rRNA of *P. jirovecii*.

Statistical analysis
--------------------

Pearson chi-square test and continuous correction chi-square test were used for assessing differences between samples. Fisher's exact test was used when the samples number \<40 or the expected value \<1. Results were considered significant at *P*\>0.05. Statistical analyses were performed using the Statistical Package for Serial Studies for personal computers (SPSS version 12; SPSS Inc., Chicago, IL, USA).

Ethics
------

This study was conducted in accordance with the amended Declaration of Helsinki, and approved by the Institutional Review Board of Shengjing Hospital and the First Affiliated Hospital, China Medical University (AF-SOP-07-1). Informed consent was obtained from all patients.

Results
=======

Ninety-eight patients were included in this study. The mean age of patients was 62±9.45 years (from 22 to 91 years old). Fifty-six (57.1%) were male. Distribution according to pulmonary diseases was 48.0% (47/98) COPD, including 15 acute stage and 32 stable stage of COPD; 25.5% (25/98) ILDs, including five idiopathic pulmonary fibrosis, five fibro-sing lung disease associated with connective tissue disease, three sarcoidosis, eight cryptogenic organizing pneumonia, and four diffuse alveolar hemorrhage; 18.4% (18/98) CF and 8.2% (8/98) CB ([Table 2](#t2-copd-10-2079){ref-type="table"}).

The LAMP assay
--------------

The results of sensitivity tested for LAMP method compared with PCR was shown in [Figure 1](#f1-copd-10-2079){ref-type="fig"}. The minimum detection limits for LAMP was 50 copies/mL, whereas the conventional PCR could amplify 10^4^ copies/mL. The specificity of the LAMP method showed that there was no cross-reaction with *C. albicans*, *C. tropicalis*, *C. parapsilosis*, and *C. glabrata*, *M. pneumoniae* (FH strain), *H. streptococcus*, methicillin-resistant *S. aureus* strains. The results of LAMP detecting the *Pneumocystis* gene in the sputum specimens of patient and the lungs of PCP model rats were positive, but it was negative in control rats. The positive results were consistent with the three examined methods, and difference of the positive and negative are apparent in [Figure 2](#f2-copd-10-2079){ref-type="fig"}.

The gene were detected in 62 (63.3%) of the 98 patients by the LAMP method and 22/98 (22.5%) by conventional PCR (*P*\<0.05). The positive rate of *P. jirovecii* was 53.2% in COPD patients, and it was 72.0%, 77.8%, and 62.5% in ILDs, CF, and CB patients, respectively ([Table 2](#t2-copd-10-2079){ref-type="table"}). No *P. jirovecii* organism was found in any of the 98 sputum specimens by Giemsa and Gomori's methenamine silver nitrate stain. The results of co-infecting identification showed that co-infecting bacteria or fungus was detected in 62 cases, and the positive rate of *P. jirovecii* was 63.3% in co-infecting patients, and 75.0% in non-co-infecting patients, but was not statistically different (*P*\>0.05). The species of microorganism in co-infecting patients were listed in [Table 3](#t3-copd-10-2079){ref-type="table"}, showing no statistical difference (*P*\>0.05). The species of co-infecting microorganism in patients with various pulmonary disease subgroups were listed in [Table 4](#t4-copd-10-2079){ref-type="table"}, no significant difference was found.

The circulating CD4^+^ lymphocyte counts were tested by the flow cytometry. The detected results are shown in [Table 5](#t5-copd-10-2079){ref-type="table"}. The *P. jirovecii* positive rate in \<410 cells/mm^3^ subjects was more than in CD~4~ counts \>410 cells/mm^3^ subjects (80.0% vs 57.5%, *P*\<0.05).

Discussion
==========

As an innovative molecular technique, LAMP requires only a heating device and isothermal conditions to amplify a specific target gene. It is a highly efficient, selective, and rapid DNA amplification technique for genetic screening of pathogens and had developed for the diagnosis of PCP.[@b10-copd-10-2079]--[@b12-copd-10-2079] In this study, we developed a LAMP method, compared with the conventional PCR method, and detected the *P. jirovecii* specific gene from sputum specimens of patients with chronic pulmonary diseases. The results showed that there was no cross-reaction with other fungi or several bacteria in detecting the specific gene of *P. jirovecii* by the LAMP method, and the minimum detection limits by the LAMP was 50 copies/mL, whereas the conventional PCR could amplify 10^4^ copies/mL, it is at least 200 times more sensitive than PCR detection for sputum specimens. The reason for the difference between the two methods was that the LAMP uses three pairs of primers, which can be amplified by the loop primers, which can greatly improve the detection efficiency. The LAMP method developed by Japanese scholars was used for the diagnosis of PCP;[@b11-copd-10-2079],[@b12-copd-10-2079] we first applied LAMP for detection the *P. jirovecii* colonization in patients with chronic pulmonary diseases. The results prove that the LAMP method is an applicable technology for evaluating the colonization of *P. jirovecii* from sputum specimens. The method is rapid, simple, cost effective, and less time-consuming.

The *P. jirovecii* is an atypical opportunistic fungus that causes pneumonia in immunosuppressed and immunocompetent individuals. The presence of *P. jirovecii* DNA in respiratory specimens without clinical signs and symptoms of pneumonia has been defined as "colonization" or "carriage", "subclinical infection" or "latent infection" *P. jirovecii* colonization in HIV-negative patients with various lung diseases has been reported.[@b2-copd-10-2079],[@b16-copd-10-2079]--[@b19-copd-10-2079] The positive rate of *P. jirovecii* DNA is 33.7%[@b16-copd-10-2079] and 70%[@b17-copd-10-2079] in bronchoalveolar lavage specimens in Turkey; 17.3% in COPD patients in North Lebanon[@b18-copd-10-2079] and 7.3% in Iranian patients with various lung diseases,[@b2-copd-10-2079] and 7.9% in COPD patients[@b19-copd-10-2079] from pulmonary specimens. All of them used the nested PCR for detected gene of *P. jirovecii*. Here, we detected the colonization of *P. jirovecii* by LAMP and PCR method in sputa of HIV (−) patients with chronic pulmonary diseases. The results show that the positive rate of *P. jirovecii* DNA was up to 63.3% by LAMP method in sputa specimens of the patients with chronic pulmonary diseases in the People's Republic of China. It is much higher than previous reports. The reason may be related to higher sensibility of LAMP (the minimum detection limits by the LAMP was 50 copies/mL) than nested PCR. The role of the higher yield of *P. jirovecii* colonization in the respiratory diseases remains to be determined. The carriers of *P. jirovecii* are at a higher risk of *P. jirovecii* pneumonia, or they may transmit the fungus to other susceptible patients.[@b7-copd-10-2079],[@b8-copd-10-2079] Preventive measures should be given more concern.

In the last few years, there is growing evidence that the lung microbe has a significant impact on clinical outcome of chronic respiratory diseases.[@b20-copd-10-2079]--[@b22-copd-10-2079] The relationship of the lung microbes with the *P. jirovecii* colonization and the role in the lung disease had drawn attention.[@b23-copd-10-2079],[@b24-copd-10-2079] We tested the microbes in sputum and investigated whether the *P. jirovecii* colonization may inhibit or promote by other microorganism in lung. The results show that more than ten microbes were discovered in the sputum in 62 patients, but did not show any statistical difference between *P. jirovecii* colonization with co-infection and those without co-infection, and even co-infection with different bacterial species. However, we detected the microbes in the sputum specimens, which could not really show the true picture of microbial population in the lung, and it is with the risk of contamination of oral microbes, despite the preventive measures taken to avoid oral microbial contamination. It will be more reliable to test the lung microbes in bronchoalveolar lavage fluid specimens.

A series of animal and human studies suggest that the *Pneumocystis* infection is strongly correlated with CD4^+^ T-cell responses.[@b25-copd-10-2079] *Pneumocystis* colonization occurred when the CD4(+) T-cell count decreased to \<500 cells/mL.[@b26-copd-10-2079] In this study, 80.0% of *Pneumocystis* gene was tested positive in the group of CD4^+^ T-cells counts \<410/mm^3^, which was significantly higher than 57.5% in the CD4^+^ T-cells counts \>410/mm^3^ group (*P*\>0.05, [Table 5](#t5-copd-10-2079){ref-type="table"}). These results support the findings of the importance of CD4^+^ T-cells in defense against *Pneumocystis*, the high prevalence of *Pneumocystis* colonization even in immunocompetent patients with high CD4^+^ T-cells counts.

The results of this study showed that prevalence of *P. jirovecii* colonization is particularly high in patients with chronic pulmonary diseases in the People's Republic of China, suggesting that those patient population is a major reservoir and source of *P. jirovecii* infection and that identification of such individuals may contribute to PCP prevention strategies. The results of detection indicate that LAMP was a good method for evaluation of the colonization of *P. jirovecii* in sputum specimen.
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![Sensitivity of LAMP method compared with PCR.\
**Notes:** Detection limit of LAMP or PCR assays were performed using serial tenfold dilutions of the *Pneumocystis* plasmid. (**A**) LAMP method: line 1, ×10^9^ copies/mL; line 2, ×10^8^ copies/mL; line 3, ×10^7^ copies/mL; line 4, ×10^6^ copies/mL; line 5, ×10^5^ copies/mL; line 6, ×10^4^ copies/mL; line 7, ×10^3^ copies/mL; line 8, ×10^2^ copies/mL; line 9, 50 copies/mL; line 10, 10 copies/mL. (**B**) PCR method: lane M, 100 bp DNA marker; lane 1, ×10^9^ copies/mL; lane 2, ×10^8^ copies/mL; lane 3, ×10^7^ copies/mL; lane 4, ×10^6^ copies/mL; lane 5, ×10^5^ copies/mL; lane 6, ×10^4^ copies/mL; lane 7, ×10^3^ copies/mL; lane 8, ×10^2^ copies/mL; lane 9, 50 copies/mL; lane 10, 10 copies/mL.\
**Abbreviations:** LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction.](copd-10-2079Fig1){#f1-copd-10-2079}

![Examination of the products of LAMP for detecting the *Pneumocystis jirovecii* gene.\
**Notes:** The products of LAMP were examined by three methods. **(A**) By real-time turbidity; (**B**) by either the naked eye or ultraviolet light after adding SYBR Green I; **(C**) by gel electrophoresis. (**A** and **B**) 1, lung of PCP positive rat; 2, sputum specimen of patient; 3, lung of PCP negative rat. (**C**) Lane M, 2,000 bp DNA marker; lane 1, lung of PCP positive rat; lane 2 and lane 3, sputum specimen of patients; lane 4, lung of PCP negative rat.\
**Abbreviations:** LAMP, loop-mediated isothermal amplification; PCP, *Pneumocystis* pneumonia.](copd-10-2079Fig2){#f2-copd-10-2079}

###### 

Primers and their sequences used in LAMP

  Primers   Sequences (5′--3′)
  --------- -----------------------------------------
  F3        ATCAGATACCGTCGTAGTCTTA
  B3        GCTCTCAATCTGTCAATCCTTA
  FIP       TTCAGCCTTGCGACCATACTCCTCGCTCGGCATCTTATG
  BIP       AAGGGCACCACCAGGAGTTATGTCTGGACCTGGTGAG
  Loop F    GGAACCCGAAGACTTTGATTTC
  Loop B    TGCGGCTTAATTTGACTCAAC

**Abbreviation:** LAMP, loop-mediated isothermal amplification.

###### 

*Pneumocystis jirovecii* colonization in patients with chronic lung diseases

  Disease                                                             Positive   Total   Positive rate (%)
  ------------------------------------------------------------------- ---------- ------- ---------------------------------------------------
  COPD                                                                25         47      53.2[\*](#tfn2-copd-10-2079){ref-type="table-fn"}
   Acute stage (AECOPD)                                               10         15      66.7[∇](#tfn3-copd-10-2079){ref-type="table-fn"}
   Stable stage                                                       15         32      46.9
  ILDs                                                                18         25      72.0
   Idiopathic pulmonary fibrosis                                      3          5       60.0
   Fibrosing lung disease associated with connective tissue disease   4          5       80.0
   Sarcoidosis                                                        2          3       66.7
   Cryptogenic organizing pneumonia                                   6          8       75.0
   Diffuse alveolar hemorrhage                                        3          4       75.0
  CF                                                                  14         18      77.8
  CB                                                                  5          8       62.5
  Total                                                               62         98      63.3

**Note:**

Compared with ILDs, CF, and CB, *P*\>0.05;

Compared with stable stage, *P*\>0.05.

**Abbreviations:** AECOPD, acute exacerbations of COPD; ILDs, interstitial lung diseases; CF, cystic fibrosis; CB, chronic bronchiectasis.

###### 

Microbes co-infection in 62 *Pneumocystis jirovecii* positive patients

  Microorganism                    Positive   Total   Positive rate (%)
  -------------------------------- ---------- ------- -------------------
  *Porphyromonas gingivalis*       10         16      62.5
  *Fusobacterium nucleatum*        15         22      68.2
  *Actinobacillus actinomycetem*   2          3       66.7
  *Tannerella forsythia*           5          9       55.6
  *Treponema pallidum*             5          13      38.5
  *Acinetobacter baumannii*        6          7       85.7
  Fungi                            8          10      80.0
  Other bacteria                   11         18      66.8
  Total                            62         98      63.3

**Note:** There were no statistically significant in difference microbe co-infection with *Pneumocystis* colonization (*P*\>0.05).

###### 

Microbe infection in the patients with difference pulmonary diseases subpopulation

  Disease   Infective microbes                                     
  --------- -------------------- ---- ---- ---- --- ---- ---- ---- ----
  COPD      4                    7    --   2    2   4    6    6    31
  ILDs      3                    5    --   --   1   2    1    4    16
  CF        2                    3    1    2    1   --   1    1    11
  CB        1                    --   1    1    1   --   --   --   4
  Total     10                   15   2    5    5   6    8    11   62

**Note:** There were no statistically significant between infective microbes in difference pulmonary diseases subpopulation (*P*\>0.05).

**Abbreviations:** *A.a*, *Actinobacillus actinomycetem*; *A.b*, *Acinetobacter baumannii*; CB, chronic bronchiectasis; CF, cystic fibrosis; *F.n*, *Fusobacterium nucleatum*; ILDs, interstitial lung diseases; *P.g*, *Porphyromonas gingivalis*; *T.f*, *Tannerella forsythia*; *T.p*, *Treponema pallidum.*

###### 

*Pneumocystis* colonization in patients with different CD4^+^ T-cells

  CD4^+^ T-cells/mm^3^   Positive   Total   Positive rate (%)
  ---------------------- ---------- ------- ---------------------------------------------------
  \<410                  20         25      80.0[\*](#tfn8-copd-10-2079){ref-type="table-fn"}
  \>410                  42         73      57.5

**Note:**

Compared with the patients with CD4^+^ T lymphocyte counts \>410/mm^3^, *P*\<0.05.
